MANKIND.BO Earnings — Mankind Pharma Limited
BSE
Updated
When is MANKIND.BO's next earnings date?
Mankind Pharma Limited (MANKIND.BO) has not announced its next earnings date yet. Its most recent earnings report was on Monday, October 26, 2026.
How did MANKIND.BO do in its last earnings report?
In its most recent report on Oct 26, 2026, Mankind Pharma Limited posted EPS of $17.20 versus the $15.22 estimate, a beat. Revenue was $43.38B against a $41.63B estimate.
How much does MANKIND.BO stock move after earnings?
MANKIND.BO beat EPS estimates in 2 of its last 2 reported quarters.
About Mankind Pharma Limited
Headquartered in New Delhi, India, Mankind Pharma Limited is a prominent developer, manufacturer, and marketer of pharmaceutical formulations and consumer healthcare products. The company's primary focus is on the Indian market, though it also boasts an international reach. Its extensive pharmaceutical portfolio addresses a broad spectrum of acute and chronic therapeutic areas, encompassing anti-infectives, cardiovascular and gastrointestinal health, anti-diabetic treatments, dermatology, pain management, neurological and CNS disorders, vitamin/mineral/nutrient supplements, and respiratory conditions. Complementing its pharmaceutical offerings, Mankind Pharma provides a variety of consumer healthcare essentials, including condoms, pregnancy detection kits, emergency contraceptives, antacid powders, dietary supplements, and anti-acne preparations. These popular products are primarily marketed under recognized brand names such as Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar. Beyond its core business, the company is involved in the trading and exporting of pharmaceutical and healthcare items, manufacturing packing materials, Ayurvedic products, bulk drugs, and consumer goods. Its diverse operations further extend into real estate, leasing, hospitality, and IT services. Mankind Pharma Limited was established in 1986.
🤖 AI Earnings Analysis
MANKIND.BO trades at 46.7× earnings with a 13.4% profit margin; valuation is demanding, leaving limited room for earnings disappointment.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-26 | 15.22 | 17.20 | — | $43.38B | ✅ Beat | — | — | — | |
| 2026-07-30 | 13.31 | 13.80 | — | $40.31B | ✅ Beat | — | — | — |
Showing last 2 quarters.